Resolution of renal disease: Mission impossible?

Journal of Nephrology

Volumn 14, Issue 3, 2001, Pages 139-145

  Lupo, A ^a   Marcantoni, C ^a   Bernich, P ^a   Maschio, G ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Ace inhibitors; Angiotensin II receptor antagonists; Glomerulosclerosis; Progression; Regression; Renal disease

Indexed keywords

ALUMINUM HYDROXIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCOSAMINOGLYCAN; HEPARIN; INDAPAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PERINDOPRIL; RAMIPRIL; STREPTOKINASE;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; GLOMERULOSCLEROSIS; HUMAN; KIDNEY DISEASE; MORPHOLOGY; NONHUMAN; PANCREAS TRANSPLANTATION; PROTEINURIA; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY DISEASES; REMISSION INDUCTION;

EID: 0034948454     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Understanding the nature of renal disease progression
2. Is there a point of no return in progressive renal disease?
3. Reversal of mesangial enlargment in rats with long-standing diabetes by whole pancreas transplantation
4. Reversal of lesions of diabetic nephropathy after pancreas transplantation
5. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
6. Inhibitory role of dietary protein restriction on the development and expression of immune-mediated anti-tubular basement membrane-induced tubulointerstitial nephritis in rats
7. Fibrinolytic therapy with streptokinase for established experimental glomerulonephritis
8. Converting enzyme inhibition and progressive glomerulosclerosis
9. Reversing glomerular hypertension stabilizes established glomerular injury
10. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions
11. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity
12. Effect of timing of antihypertensive therapy on glomerular injury: Comparison between captopril and diltiazem
13. Evidence that an angiotensin converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started
14. Severity of renal damage at the start of ace inhibitor treatment determines long term renal outcome in fawn-hooded (FHH) rats
15. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis
16. Effects of delayed treatment with enalpril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats
17. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy
18. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy
19. Ace inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy
20. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease
21. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure
22. L-Arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats
23. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney
24. Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy
25. Influence of the renal medulla and early treatment with enalapril upon the development of hypertension in young spontaneously hypertensive rats
26. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease
27. Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats
28. Dietary protein restriction in established renal injury in the rat
29. Therapeutic implications of converting-enzyme inhibitors in renal disease
30. Importance of early initiation of dietary protein restriction for the prevention of experimental progressive renal disease
31. Effects of antihypertensive drugs on glomerular morphology
32. Role for uremic toxin in the progressive loss of intact nephrons in chronic renal failure
33. Advantage of early initiation of aluminium hydroxide administration for the prevention of experimental progressive renal disease
34. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis
35. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in unnephrectomized SHR
36. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy
37. Blood-pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure
38. Regression of established glomerulosclerosis by high dose angiotensin type 1 receptor antagonist (AIIRA) is linked to inhibition of plasminogen activator inhibitor-1 (PAI-1)
39. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms
40. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria
41. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
42. Effects of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
43. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure
44. Angiotensin II receptor blockers in type 2 diabetic patients with microalbuminuria
45. Early intervention in microalbuminuria. 24-h BP and exercise changes
46. Is remission/regression of diabetic nephropathy possible?
47. Regression of microalbuminuria in type II diabetic, hypertensive patients after long term indapamide treatment
48. Remission of nephrotic range proteinuria in type I diabetes
49. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
50. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabets mellitus
51. Effect of glycemic control on early diabetic renal lesions
52. Renal interstitial expansion is modified by perindopril in true diabetic glomerulosclerosis in type 2 NIDDM diabetic patients. A 2-year sequential biopsy study
53. Early dietary protein restriction protects the failing kidney
54. Hypertension and progression of renal failure in patients on protein-restricted diet
55. Renal function in IgA nephropathy with established renal failure
56. Chronic renal failure in India
57. The point of no return and the rate of progression in the natural history of IgA nephritis
58. Lisinopril in hypertensive patients with renal function impairment
59. Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and β-blocking agents
60. Long-term effects of felodipine in patients with reduced renal function
61. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
62. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy
63. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
64. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GRF
65. Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria